论文部分内容阅读
目的探讨可溶性白细胞介素２受体（ｓＩＬ－２Ｒ）、肿瘤坏死因子α（ＴＮＦα）及其可溶性受体Ⅰ型（ｓＴＮＦ－ＲⅠ）在皮肤Ｔ细胞性淋巴瘤（ＣＴＣＬ）发病机制中的作用。方法采用单克隆和多克隆双抗体夹心法，测定ＣＴＣＬ患者和对照组血清标本中ｓＩＬ－２Ｒ、ＴＮＦα和ｓＴＮＦ－ＲⅠ，同时测定血清乳酸脱氢酶（ＬＤＨ）水平。结果ＣＴＣＬ患者血清ｓＩＬ－２Ｒ水平明显高于对照组（Ｐ＜０．０１），同时ｓＩＬ－２Ｒ增高的比例在不同的临床分期中也不同，其中，血清中ｓＩＬ－２Ｒ在Ⅳ期病人中明显高于Ⅰ、Ⅱ期（Ｐ＜０．０５）。治疗有效时，ｓＩＬ－２Ｒ水平下降。ｓＩＬ－２Ｒ水平与血ＬＤＨ无相关性。ＴＮＦα水平明显高于正常对照组（Ｐ＜０．０１），ｓＴＮＦ－ＲⅠ除个别升高外，大部分在正常范围内，且与分期无相关（Ｐ＞０．０５）。结论测定血清ｓＩＬ－２Ｒ可作为ＣＴＣＬ患者病情判断、疗效观察及估计预后的生物学指标。而ＴＮＦ的升高，表明细胞因子参与了肿瘤的发生和发展。
Objective To investigate the role of soluble interleukin 2 receptor (sIL-2R), tumor necrosis factor α (TNFα) and soluble receptor type I (sTNF-RI) in the pathogenesis of cutaneous T-cell lymphoma (CTCL). METHODS: The levels of sIL-2R, TNFα and sTNF-RI in serum specimens of patients with CTCL and controls were measured by a monoclonal and polyclonal sandwich method. Serum lactate dehydrogenase (LDH) levels were measured. Results Serum levels of sIL-2R in patients with CTCL were significantly higher than those in the control group (P<0.01), while the proportion of sIL-2R increased was also different in different clinical stages. Serum sIL-2R was significantly increased in patients with stage IV. Higher than stage I and II (P<0.05). When treatment is effective, sIL-2R levels decline. There was no correlation between sIL-2R levels and blood LDH. The level of TNFα was significantly higher than that of the normal control group (P<0.01). Most of the sTNF-RI were in the normal range except for a few increase, and there was no correlation with the stage (P>0.05). Conclusion Determination of serum sIL-2R can be used as a biological indicator for the judgment of the condition of patients with CTCL, curative effect observation and prognosis estimation. The increase of TNF indicates that cytokines are involved in the occurrence and development of tumors.